REMARKS

Claim Amendment and New Claims 53

By virtue of this amendment, claims 20-49 and 51-52 have been cancelled, claim 50 has been amended and claim 53 has been added. Support for the claim amendment and new claim can be found throughout the specification and originally filed claims. No new matter has been added as a result of the amendment and entry thereof is respectfully requested.

As new claim 53 depends from claim 50 and thus, is drawn to a method of immunizing a human against pertussis, Applicants request that claim 53 be examined with the Group III claims.

Restriction Requirement

Responsive to the Restriction Requirement, Applicants elect the claims of Group III (claim 50 and new claims 53), drawn to a method of immunizing a human against pertussis comprising administering a vaccine comprising a specific modified S1 subunit of pertussis toxin, for prosecution.

Applicants reserve the right to file a continuing application or take such other appropriate action as deemed necessary to protect the non-elected inventions.

Respectfully submitted,

NOVARTIS VACCINES AND DIAGNOSTICS, INC.

Registration No. 39,270

Telephone: (510) 923-2192 Facsimile: (510) 655-3542

Emeryville, CA 94662-8097

Dated: December 26, 2006.